Sepsis is the leading cause of death globally, affecting 49 million people and resulting in 11 million deaths each year. In the USA alone, it impacts over 2 million individuals annually, significantly increasing ICU and hospital stays. Current treatments primarily focus on stabilization rather than curing the underlying condition.
The economic burden of sepsis on the U.S. healthcare system exceeds $62 billion annually, accounting for a significant portion of ICU expenditures.
Despite efforts to develop new therapeutic modalities, current therapeutic options remain very limited. The lack of effective therapeutic interventions highlights the urgent need for targeted therapies to improve outcomes and reduce the economic impact of this pervasive condition.
AKI affects almost 4 million people in the United States with an annual cost of up to $24.0 billion. The most expensive patients are those with AKI of sufficient severity to require dialysis, where cost increases relative to patients without AKI and can reach up to $42,000 per hospitalization event.
In-hospital, mortality for patients with Sepsis & SA-AKI has recently been estimated around 30%, while critically ill patients with dialysis-requiring AKI experience mortality rates can excess to 60%. Despite efforts to develop new therapeutic modalities, current therapeutic options are very limited.
Eliaz Therapeutics is pioneering a groundbreaking medical device designed to selectively remove galectin-3 (Gal-3) from the bloodstream.
Galectin-3 is a crucial mediator that drives organ inflammation and fibrosis across various acute and chronic conditions. Elevated levels of Gal-3 in critically ill patients correlate with the onset of Sepsis and Acute Kidney Injury (AKI). Studies in animal models show that blocking Gal-3 significantly reduces rates of Sepsis and Sepsis-Associated AKI (SA-AKI), and enhances survival rates.
XGAL-3® is a pioneering patented platform technology that selectively removes the root cause - Galectin-3 from the bloodstream through targeted therapeutic apheresis.
Find out how we have developed the technology to target and remove Gal-3 directly from the bloodstream.
"Sepsis associated with 1 in 5 deaths globally..."
"...In 2017, an estimated 48.9 million (95% uncertainty interval [UI] 38.9-62.9) incident cases of sepsis were recorded worldwide and 11.0 million (10.1-12.0) sepsis-related deaths were reported, representing 19.7% (18.2-21.4) of all global deaths.
Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study.
The Lancet, 2020; DOI: 10.1016/S0140-6736(19)32989-7
Medical Device for Removal of Galectin-3
Studies demonstrate that Gal-3 has a causal role in AKI. AKI mediates not only local injury but also induces remote cardiac dysfunction, injury, and fibrosis via a gal-3-dependent pathway. Gal-3’s causal role in AKI makes it a potential point of therapeutic intervention.
Galectin-3 (Gal-3) is a protein naturally produced by our bodies, but its levels can increase over time due to factors like stress, injury, and ageing. Research from over 3,000 studies has shown that Gal-3 plays a significant role in a variety of health problems. Many chronic conditions that affect us and our loved ones are linked to the harmful effects of this protein.
.jpg)
Gal-3 is also associated with the progression of diabetes, heart failure, cancer, as well as liver and lung fibrosis. We have developed a unique medical device to allow Gal-3 removal from the circulation.
By targeting Gal-3 and selectively removing it from the bloodstream, we stop the rapid kidney function deterioration and effectively prevent long-term debilitating illnesses.
The addition of an extracorporeal procedure to intervene at an early stage to potentially slow down an aggressive disease or enhance the effectiveness of other therapies.
A recent proof-of-concept study shows that the removal of Gal-3 through a prototype device concept is both feasible and effective, yielding dramatic results in an induced fibrosis model.
The results, supported by previous models with Gal-3 inhibitors and genetic knockout animals, indicate that the removal of Gal-3 from the circulation can revolutionize the care of CKD patients, as well as of other potential Gal-3 mediated diseases including heart failure and cancer.
The single-use X-Gal-3 apheresis column selectively removes Galectin-3 from the body. Containing proprietary, highly effective molecule capturing, X-Gal-3 is built in a format that hospitals already know how to use.
